Ionis Pharmaceuticals, News - ISIS

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

CARLSBAD, Calif., Jan. 5 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials...

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

OGX-011 Phase 3 Studies in First- and Second-Line Advanced Prostate Cancer and Non-Small Cell Lung Cancer Expected to Begin in 2010 and Early 2011...

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your...

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

CARLSBAD, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis 2Q Loss Narrows, Helped By Genzyme Partnership

Isis Pharmaceuticals Inc.'s (ISIS) second-quarter loss narrowed, helped by revenue generated by its partnership with Genzyme Corp. (GENZ), as the...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

- Conference Call Webcast Thursday, August 6, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

UPDATE: Genzyme, Isis Cholesterol Drug Data Raise Questions

Genzyme Corp. (GENZ) and Isis Pharmaceuticals Inc. (ISIS) reported the success of a late-stage trial of cholesterol treatment mipomersen, but Wall...

Genzyme, Isis Cholesterol Drug Meets Goal In Late Study

Genzyme Corp. (GENZ) and Isis Pharmaceuticals Inc. (ISIS) said its mipomersen drug cut so-called bad cholesterol levels by 25% in a late-stage...

Isis Swings To 1Q Profit Amid Gain, Partnership Revenue

Isis Pharmaceuticals Inc. (ISIS) swung to a first-quarter profit as revenue generated by its partnership with Genzyme Corp. (GENZ) and a gain from...

OncoGenex Appoints New CFO and Board Member

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., announced the appointment of Mr. Stephen Anderson as Chief Financial...

OncoGenex Announces Completion of $12.8 Million Venture Financing

VANCOUVER, Aug. 16 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted...

SAR - Universe Grp.

RNS Number:6769U ISIS Asset Management PLC 27 January 2004 FORM SAR 5 Date of disclosure 27TH JANUARY 04 DISCLOSURE UNDER NOTE 3...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ionis Pharmaceuticals, (ISIS)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ISIS News

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis 2Q Loss Narrows, Helped By Genzyme Partnership

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

UPDATE: Genzyme, Isis Cholesterol Drug Data Raise Questions

Genzyme, Isis Cholesterol Drug Meets Goal In Late Study

Isis Swings To 1Q Profit Amid Gain, Partnership Revenue

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

SAR - Universe Grp.

ISIS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ionis Pharmaceuticals, (ISIS) News

Ionis Pharmaceuticals, (ISIS)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ISIS News

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis 2Q Loss Narrows, Helped By Genzyme Partnership

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

UPDATE: Genzyme, Isis Cholesterol Drug Data Raise Questions

Genzyme, Isis Cholesterol Drug Meets Goal In Late Study

Isis Swings To 1Q Profit Amid Gain, Partnership Revenue

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

SAR - Universe Grp.

ISIS Discussion

Your Recent History